医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集
▼×

感染症

China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection

China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection

AIDS バイオテクノロジーヘルスケア感染症病院臨床試験製薬　 TimeLine: China National Drug Administration Approves Emtricitabine and Tenofovir Alafenamide Single Tablet Regimen for the Treatment

2018年08月06日

0

Strong Occupational Health & Safety Programmes Can Provide a Business Advantage for Multinational Organisations in the Talent Driven India Market

Strong Occupational Health & Safety Programmes Can Provide a Business Advantage for Multinational Organisations in the Talent Driven India Market

ヘルスケアヘルス一般感染症　 TimeLine: Advantage for Multinational Organisations in the Safety Programmes Can Provide a Business Strong Occupational Health

2018年08月06日

0

Shionogi Announces FDA Approval of Mulpleta® (Lusutrombopag)

Shionogi Announces FDA Approval of Mulpleta® (Lusutrombopag)

ヘルスケアヘルス一般外科感染症病院臨床試験製薬　 TimeLine: Shionogi Announces FDA Approval of Mulpleta

2018年08月01日

0

Blade Therapeutics Announces Initiation of Phase 1 Study of Lead Calpain Inhibitor BLD-2660 for Fibrosis

Blade Therapeutics Announces Initiation of Phase 1 Study of Lead Calpain Inhibitor BLD-2660 for Fibrosis

バイオテクノロジーヘルスケア感染症臨床試験製薬　 TimeLine: Blade Therapeutics Announces Initiation of Phase 1 Calpain Inhibitor BLD-2660 for Fibrosis

2018年07月17日

0

Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu

Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms in People at High Risk of Complications From the Flu

バイオテクノロジーヘルスケア感染症臨床試験製薬　 TimeLine: Phase III CAPSTONE-2 Study Showed That Baloxavir Symptoms in People at High Risk

2018年07月17日

0

森永乳业的专利免疫原性成分LAC-Shield(TM)获得自我检定GRAS认证

森永乳业的专利免疫原性成分LAC-Shield(TM)获得自我检定GRAS认证

バイオテクノロジーヘルスケア感染症　 TimeLine: 森永乳业的专利免疫自我检定GRAS

2018年07月06日

0

Morinaga Milk Obtains Self-Affirmed GRAS Status for Its Proprietary Immunogenic Ingredient LAC-Shield(TM)

Morinaga Milk Obtains Self-Affirmed GRAS Status for Its Proprietary Immunogenic Ingredient LAC-Shield(TM)

バイオテクノロジーヘルスケア感染症　 TimeLine: Immunogenic Ingredient LAC-Shield Morinaga Milk Obtains Self-Affirmed GRAS Status

2018年07月06日

0

Gore Announces First Commercial In-Human Use of GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System for TEVAR in Australia

Gore Announces First Commercial In-Human Use of GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System for TEVAR in Australia

バイオテクノロジーヘルスケアヘルス一般医療機器外科心臓学感染症　 TimeLine: Gore Announces First Commercial In-Human Use Thoracic Stent Graft with ACTIVE CONTROL System

2018年07月03日

0

Global Virus Network (GVN) Centers of Excellence Contribute Expertise to Nipah Virus Outbreak in Kerala, India

Global Virus Network (GVN) Centers of Excellence Contribute Expertise to Nipah Virus Outbreak in Kerala, India

ヘルスケア感染症　 TimeLine: Excellence Contribute Expertise to Nipah Virus Global Virus Network

2018年06月06日

0

Shionogi Announces Upcoming Presentations at American Society for Microbiology Microbe Meeting

Shionogi Announces Upcoming Presentations at American Society for Microbiology Microbe Meeting

バイオテクノロジーヘルスケア感染症臨床試験製薬　 TimeLine: Microbiology Microbe Meeting Shionogi Announces Upcoming Presentations

2018年06月05日

0